In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, against Enterococcus faecalis

Chemotherapy. Nov-Dec 1996;42(6):432-8. doi: 10.1159/000239476.

Abstract

In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, were assessed against Enterococcus faecalis. In vitro, TOC-50 had excellent activity, stronger than that of penicillin G, sulbactam/ampicillin, tazobactam/piperacillin, the cephalosporins tested, imipenem, vancomycin, gentamicin, tobramycin, arbekacin, amikacin, minocycline and ofloxacin against clinically isolated strains. In addition, TOC-50 was more active than penicillin G, sulbactam/ampicillin and imipenem against vancomycin-resistant E. faecalis NCTC 12201. In terms of bactericidal effect against the same strain, TOC-50 was superior to sulbactam/ampicillin and imipenem. In murine systemic infection models, TOC-50 had a potent protective activity against E. faecalis 42. Its protective activity was stronger than that of imipenem or vancomycin.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Cephalosporins / pharmacology*
  • Drug Evaluation, Preclinical
  • Enterococcus faecalis / drug effects*
  • Imipenem / pharmacology
  • Injections, Subcutaneous
  • Male
  • Mice
  • Mice, Inbred Strains
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • TOC 50
  • Vancomycin
  • Imipenem